TAO Synergies (TAOX) Other Non-Current Liabilities (2021 - 2026)
TAO Synergies' (TAOX) quarterly Other Non-Current Liabilities came in at $2.8 million in Q2 2026, up 268.22% on a YoY basis from $752000.0 in Q2 2025, and down 26.43% quarter-over-quarter from $3.8 million in Q1 2026.
Analysis
TAO Synergies (TAOX) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Other Non-Current Liabilities for 6 consecutive years, with $2.8 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Other Non-Current Liabilities rose 268.22% year-over-year to $2.8 million; the trailing twelve-month figure through Jun 2026 stood at $2.8 million (up 268.22% YoY), and the FY2025 full-year result was $2.1 million, down 65.78% from the prior year.
- Other Non-Current Liabilities retreated to $2.8 million in Q2 2026 per TAOX's latest filing, from $3.8 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $6.3 million in Q1 2025 and bottomed at $141000.0 in Q1 2024.
- Historically, Other Non-Current Liabilities has averaged $2.5 million across 5 years, with a median of $1.7 million in 2023.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities slumped 91.02% in 2024, then soared 4336.88% in 2025.
- Over 5 years, Other Non-Current Liabilities stood at $1.5 million in 2022, then declined by 26.29% to $1.1 million in 2023, then jumped by 454.99% to $6.2 million in 2024, then plunged by 65.78% to $2.1 million in 2025, then jumped by 30.98% to $2.8 million in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $2.8 million, $3.8 million, and $2.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn |
| 10 | TAO Synergies | 30.79 Mn | 30.79 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.77 Mn |
| Mar 31, 2026 | 3.76 Mn |
| Dec 31, 2025 | 2.11 Mn |
| Sep 30, 2025 | 646,000.00 |
| Jun 30, 2025 | 752,000.00 |
| Mar 31, 2025 | 6.26 Mn |
| Dec 31, 2024 | 6.18 Mn |
| Sep 30, 2024 | 6.12 Mn |
| Jun 30, 2024 | 236,000.00 |
| Mar 31, 2024 | 141,000.00 |
| Dec 31, 2023 | 1.11 Mn |
| Sep 30, 2023 | 1.66 Mn |
| Jun 30, 2023 | 2.63 Mn |
| Mar 31, 2023 | 922,000.00 |
| Dec 31, 2022 | 1.51 Mn |
| Dec 31, 2021 | 9.90 Mn |